CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 85.24% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money
1.5047
0%
  • Summary
  • Historical Data
Trading сonditions
Spread 0.1506
Long position overnight fee

Long position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment -0.023624 %
Charges from full value of position ($-4.49)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.023624%
Short position overnight fee

Short position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment 0.001401 %
Charges from full value of position ($0.27)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.001401%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5.00%
Stock exchange United States of America
Commission on trade 0%

Key Stats
Prev. Close 1.5047
Open 1.4847
1-Year Change -57.55%
Day's Range 1.4547 - 1.5047
  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Apr 1, 2025 1.5047 0.0500 3.44% 1.4547 1.5047 1.4547
Mar 31, 2025 1.4147 0.0600 4.43% 1.3547 1.4147 1.3247
Mar 28, 2025 1.3547 -0.0300 -2.17% 1.3847 1.3947 1.3547
Mar 27, 2025 1.4247 0.0000 0.00% 1.4247 1.4547 1.4247
Mar 26, 2025 1.4447 -0.0700 -4.62% 1.5147 1.5147 1.3947
Mar 24, 2025 1.5247 -0.0500 -3.18% 1.5747 1.5747 1.4747
Mar 21, 2025 1.5547 -0.0200 -1.27% 1.5747 1.6047 1.5347
Mar 20, 2025 1.5747 -0.0400 -2.48% 1.6147 1.6147 1.5747
Mar 19, 2025 1.5847 -0.0400 -2.46% 1.6247 1.6347 1.5747
Mar 18, 2025 1.6547 0.0300 1.85% 1.6247 1.6547 1.6247
Mar 17, 2025 1.6647 0.0400 2.46% 1.6247 1.6647 1.6247
Mar 14, 2025 1.6547 -0.0400 -2.36% 1.6947 1.6947 1.6547
Mar 13, 2025 1.7147 0.1000 6.19% 1.6147 1.7147 1.6147
Mar 12, 2025 1.6147 -0.0300 -1.82% 1.6447 1.6847 1.5947
Mar 11, 2025 1.6047 0.0400 2.56% 1.5647 1.6247 1.5647
Mar 10, 2025 1.6047 0.0300 1.91% 1.5747 1.6447 1.5747
Mar 7, 2025 1.6147 0.0500 3.20% 1.5647 1.6447 1.5247
Mar 6, 2025 1.6247 0.0200 1.25% 1.6047 1.6347 1.5847
Mar 5, 2025 1.6247 0.0500 3.18% 1.5747 1.6247 1.5747
Mar 4, 2025 1.6347 0.0300 1.87% 1.6047 1.6347 1.5647

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
  • 2:1
  • 3:1
  • 5:1
  • 10:1
  • 20:1
Leverage
20:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

BeyondSpring Inc. Company profile

About Beyondspring Inc

BeyondSpring Inc. is a global biopharmaceutical company that is focused on developing immuno-oncology cancer therapies. The Company’s lead product Plinabulin, which is being studied as an anti-cancer agent in combination with docetaxel in advanced non-small cell lung cancer (NSCLC). The Plinabulin product is a marine-derived small-molecule selective immunomodulating microtubule-binding agent (SIMBA) with a range of immune activities. Its Plinabulin has the immune defense protein, GEF-H1, which leads to two effects: a durable anti-cancer benefits due to the maturation of dendritic cells resulting in activation of tumor antigen-specific T-cells to target cancer cells and early-onset action in chemotherapy-induced neutropenia (CIN) prevention after chemotherapy by boosting the number of hematopoietic stem/progenitor cells (HSPCs).

Financial summary

BRIEF: For the nine months ended 30 September 2021,Beyondspring Inc revenues increased from $0K to $1M. Netloss increased 26% to $54.7M. Revenues reflect an increasein demand for the Company's products and services due tofavorable market conditions. Higher net loss reflectsGeneral and administrative - Balancing increase from $10.2Mto $22M (expense), Stock-based Compensation in SGA increaseof 76% to $3.7M (expense).

Industry: Bio Therapeutic Drugs

28 Liberty Street
39th Floor
NEW YORK
NEW YORK 10005
US

People also watch

US100

18,687.30 Price
-3.680% 1D Chg, %
Long position overnight fee -0.0236%
Short position overnight fee 0.0014%
Overnight fee time 21:00 (UTC)
Spread 1.8

ETH/USD

1,795.78 Price
-6.200% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 1.75

XRP/USD

2.04 Price
-5.460% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 0.01016

BTC/USD

82,527.25 Price
-3.230% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 50.00

Still looking for a broker you can trust?

Join the 710,000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading